Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) Short-Term Debt issuances: 2021-2025

Historic Short-Term Debt issuances for Aytu Biopharma (AYTU) over the last 4 years, with Sep 2025 value amounting to $5.8 million.

  • Aytu Biopharma's Short-Term Debt issuances rose 209.87% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 247.07%. This contributed to the annual value of $6.7 million for FY2025, which is 701.44% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Short-Term Debt issuances is $5.8 million, which was up 702.07% from -$965,000 recorded in Q2 2025.
  • Aytu Biopharma's 5-year Short-Term Debt issuances high stood at $42.2 million for Q3 2021, and its period low was -$43.0 million during Q4 2021.
  • For the 3-year period, Aytu Biopharma's Short-Term Debt issuances averaged around $676,727, with its median value being $555,000 (2024).
  • Per our database at Business Quant, Aytu Biopharma's Short-Term Debt issuances slumped by 2,165.42% in 2023 and then skyrocketed by 983.96% in 2025.
  • Aytu Biopharma's Short-Term Debt issuances (Quarterly) stood at -$43.0 million in 2021, then soared by 98.47% to -$658,000 in 2022, then spiked by 71.28% to -$189,000 in 2023, then tumbled by 36.51% to -$258,000 in 2024, then spiked by 209.87% to $5.8 million in 2025.
  • Its Short-Term Debt issuances stands at $5.8 million for Q3 2025, versus -$965,000 for Q2 2025 and $6.0 million for Q1 2025.